Researchers at Duke-National University of Singapore (Duke-NUS) Medical School have discovered for the first time that interleukin-11 (IL-11) may be an important therapeutic target for cardiovascular (CV) fibrotic diseases, including heart and renal failure, they reported in the Nov. 13, 2017, edition of Nature.